Business Context and Reporting Period
ImmunityBio, Inc. (IBRX) is a vertically-integrated biotechnology company focused on developing immunotherapies and vaccines. The reporting period covers the three and nine months ended September 30, 2024. The company's lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), received FDA approval on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Commercial distribution began in May 2024. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Sept 30, 2024 Balance Sheet |
|---|---|---|---|
| Total Revenue | $6.1 million | $7.2 million | N/A |
| Product Revenue (ANKTIVA) | $6.0 million | $6.9 million | N/A |
| Net Loss (Attributable to Common Stockholders) | $(85.7) million | $(354.4) million | N/A |
| Operating Loss | $(80.3) million | $(274.8) million | N/A |
| Research & Development Expense | $50.4 million | $154.9 million | N/A |
| Selling, General & Administrative Expense | $35.9 million | $127.1 million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $112.0 million |
| Marketable Securities | N/A | N/A | $18.4 million |
| Total Debt (Related-Party Notes) | N/A | N/A | $699.1 million (net of discounts) |
| Revenue Interest Liability | N/A | N/A | $273.7 million |
| Warrant Liabilities | N/A | N/A | $18.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased from $82,000 in Q3 2023 to $6.1 million in Q3 2024, driven entirely by the commercial launch of ANKTIVA. For the nine months ended September 30, 2024, revenue was $7.2 million compared to $483,000 in the prior year period.
- Operating Expenses: R&D expenses decreased by $25.9 million for the nine-month period compared to 2023, primarily due to reduced external CMO fees and clinical trial costs. SG&A expenses increased by $30.5 million for the nine-month period, driven by higher legal fees and consulting costs related to commercial readiness.
- Other Income/Expense: The company recorded a $31.3 million gain from the change in fair value of warrant liabilities in Q3 2024. Interest expense related to the Revenue Interest Purchase Agreement (RIPA) was $10.9 million in Q3 2024, a new line item not present in the prior year.
- Liquidity: Cash and cash equivalents decreased from $265.5 million at year-end 2023 to $112.0 million at September 30, 2024, reflecting operating cash outflows of $306.1 million for the nine-month period.
Guidance, Outlook, and Risks
- Commercialization: Management expects it will take time to generate significant revenue from ANKTIVA. The company secured coverage for over 200 million medical lives and received a J-code effective January 1, 2025. Marketing authorization applications (MAA) are planned for the UK and EU in late 2024.
- Liquidity and Going Concern: The company states that substantial doubt exists regarding its ability to continue as a going concern without additional funding. Management believes existing cash, marketable securities, product sales, and potential borrowings from affiliated entities (specifically Dr. Soon-Shiong) will fund operations for at least the next 12 months.
- Debt Obligations: The company has significant debt obligations, including $735 million in related-party promissory notes (principal) and a $300 million revenue interest liability. The RIPA requires quarterly payments based on a percentage of net sales (tiered 4.5% to 10.0%) and includes a "True-Up Payment" obligation if cumulative payments do not meet a threshold by December 31, 2029.
- Legal Proceedings: The company is involved in a securities class action lawsuit regarding prior FDA Complete Response Letters (CRL) and a shareholder derivative action. Additionally, an arbitration with Shenzhen Beike Biotechnology regarding a China license agreement is scheduled for hearing in June 2025.
- Manufacturing: The company received notice of non-compliance regarding employee count requirements at its Dunkirk Facility lease, which could impact tax incentives and lease terms if not resolved.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of ANKTIVA sales and the impact of the J-code implementation in January 2025 on reimbursement and adoption rates.
- Debt Service Capacity: Assess the company's ability to service the $735 million in related-party debt and the variable RIPA payments without immediate additional equity financing.
- Going Concern Status: Monitor the company's cash burn rate and the actual availability of additional funding from affiliated entities (Dr. Soon-Shiong) to support operations beyond the 12-month horizon.
- Legal Exposure: Track the status of the securities class action and the Beike arbitration, as adverse outcomes could result in significant financial liabilities or operational restrictions.
- Manufacturing Compliance: Confirm the resolution of the Dunkirk Facility employee count dispute to ensure continued access to the facility and associated tax benefits.